Narayana Hrudayalaya (NH) Q2 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 26/27 earnings summary
2 Nov, 2026Executive summary
Q2 FY27 consolidated revenue was ₹28,439.89m, up 73.0% YoY; EBITDA was ₹6,054.15m and continuing-operations net profit ₹3,011.53m.
India hospital growth was driven by higher volumes and price mix; management prioritizes patient access and volume over targeting a specific margin.
International operations are pursuing cost efficiencies and integrated care, with UK revenue recovery and insurance profitability key execution priorities.
H1 FY27 consolidated revenue was ₹55,276.23m, EBITDA ₹11,105.93m and continuing-operations net profit ₹5,084.23m.
Financial highlights
Q2 consolidated EBITDA was ₹6,054.15m, up 42.0% YoY; EBITDA margin was 21.3% versus 25.9% in Q2 FY26.
Continuing-operations net profit was ₹3,011.53m versus ₹2,584.95m a year earlier; net profit margin was 10.59% versus 15.71%.
India hospital EBITDA margin was 26.8%, or 23.6% excluding other income; doctor and nursing costs fell 1.8% through operating leverage.
India inpatient volumes rose 4% YoY and outpatient footfall 12% YoY; inpatient footfall was up 6% QoQ and nearly 4% YoY.
Combined India insurance and clinic losses fell to INR 20 crore from INR 33 crore in the prior quarter; India insurance reported a ₹151m PAT loss in Q2.
Outlook and guidance
Management expects stronger India inpatient and outpatient footfalls in Q3 and Q4, supported by recent volumes and patient funnels across regions.
India average length of stay is targeted to move toward 4.0–4.1 days over four to six quarters, subject to high-acuity and transplant case mix.
UK returns should be assessed over five to seven years; management expects to bridge the 4%–5% group ROCE dilution from the UK over roughly five years.
Cayman plans major insurance repricing in July 2027 and expects to exit most unprofitable books from then; losses are expected to become negligible before that.
Bed capacity target is 7,800+ by FY30; FY27 capex plans are ₹4,600m for greenfield/inorganic projects and ₹2,700m for replacement and maintenance.
Latest events from Narayana Hrudayalaya
- Record revenue, profit, and margin growth with strong expansion and digital transformation.NH
Q4 23/24 - Revenue up 78% YoY, EBITDA at ₹5,052m, India margins strong, U.K. faces short-term disruption.NH
Q1 26/27 - FY26 revenue up 44% YoY, strong margins, UK expansion, and ₹4.50 dividend proposed.NH
Q4 25/26 - Q3 FY26 delivered 61.2% YoY revenue growth, robust expansion, and UK integration.NH
Q3 25/26 - Q1 FY25 saw record revenue, margin expansion, and new health insurance operations amid robust growth.NH
Q1 24/25 - Q2 FY25 delivered revenue growth, margin gains, digital progress, and 1,500 new beds planned.NH
Q2 24/25 - Q3 FY25 saw robust growth, margin gains, digital progress, and disciplined expansion.NH
Q3 24/25 - Strong FY25 revenue and EBITDA growth, dividend, NCD issuance, and expansion plans.NH
Q4 24/25 - Q1 FY26 delivered strong revenue and margin growth, with expansion and digitalization ongoing.NH
Q1 25/26